Mitochon Pharmaceuticalsincis A Clinical Stage Biotechnology Company Based In Radnorpennsylvaniathe Company Is Dedicated To Developing Therapies That Target Mitochondrial Dysfunctionwhich Is Linked To Serious Neurodegenerativeneuromuscularand Metabolic Diseasesfounded By Ceo Robert Alonsowho Has Over 25 Years Of Experience In The Pharmaceutical Industrymitochon Aims To Address The Root Causes Of These Diseases Through Innovative Micro Dosed Therapies Mitochonae S Pipeline Includes Mp 101A Small Molecule Drug Currently In Phase 2 Trials For Huntingtonae S Diseaseand Mp 201A Preclinical Stage Bdnf Modulator For Optic Neuritis And Other Demyelinating Conditionsthe Company Holds Nine Patents Related To Rare Diseases And Autoimmune Conditionsfocusing On Mechanisms That Stimulate Mitochondrial Proteins And Modulate Bdnfmitochon Targets A Range Of Therapeutic Areasincluding Neurodegenerative Diseases Like Alzheimerae S And Alsas Well As Neuromuscular Disorders And Metabolic Conditions
No conferences found for this company.
| Company Name | Mitos Pharmaceuticals Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
